<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04467242</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL20_0372</org_study_id>
    <nct_id>NCT04467242</nct_id>
  </id_info>
  <brief_title>Right Ventricular Diastolic Dysfunction</brief_title>
  <acronym>RVDD</acronym>
  <official_title>Interaction Between Right Heart Dysfunction and Emphysema: Impact of Endoscopic Lung Volume Reduction (RVDD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart-lung interactions remain misunderstood whereas pulmonary and cardiac pathologies are&#xD;
      very commonly associated.&#xD;
&#xD;
      Emphysema by increasing intrathoracic pressure appears to affect cardiac function.&#xD;
&#xD;
      Interestingly, previous studies have shown a link between the telediastolic volume of the&#xD;
      right ventricle (measured by RMI) and the intensity of emphysema.&#xD;
&#xD;
      Our hypothesis is that the emphysema by increasing intrathoracic pressure leads to or&#xD;
      accentuates right cardiac diastolic dysfunction by decreasing compliance and cardiac preload.&#xD;
&#xD;
      To verify this hypothesis the investigators will perform KT loop procedures in order to&#xD;
      acquire intracardiac pressure/volume curves before and after lung volume reduction.&#xD;
&#xD;
      The pressure/volume curves allow the analysis of systolic and diastolic function, cardiac&#xD;
      contractility and loading conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate the change in right diastolic cardiac function after reduction of emphysema</measure>
    <time_frame>1 day</time_frame>
    <description>Estimate the change in right diastolic cardiac function after reduction of emphysema : assessed by the change in the slope end diastolic pressure volume relationship (EDPVR mmHg/ml) obtained by KT Loop procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimate the change in right systolic heart function</measure>
    <time_frame>1 day</time_frame>
    <description>Estimate the change in right systolic heart function before and after reduction of emphysema assessed by the cardiac output (L/min), the stroke volume (ml), the end systolic pressure (mmHg), the end systolic volume (mmHg), obtained by KT Loop procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the change in right cardiac contractility</measure>
    <time_frame>1 day</time_frame>
    <description>Estimate the change in right cardiac contractility before and after reduction of emphysema assessed by the slope end systolic pressure volume relationship (mmHg/ml), obtained by KT Loop procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate ventriculo-arterial coupling</measure>
    <time_frame>1 day</time_frame>
    <description>Estimate ventriculo-arterial coupling before and after reduction of emphysema assessed by the Ees/Ea ratio, obtained by KT Loop procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the evolution of symptoms assessed</measure>
    <time_frame>1 day</time_frame>
    <description>Evaluate the evolution of symptoms assessed by the Mmrc questionnaire and the CATCOPD questionnaire before and after reduction of emphysema.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing exercice performance</measure>
    <time_frame>1 day</time_frame>
    <description>Assessing exercice performance by the 6 minutes walk test before and after reduction of emphysema.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the evolution of respiratory function</measure>
    <time_frame>1 day</time_frame>
    <description>Evaluate the evolution of respiratory function before and after reduction of emphysema assessed by the FEV1 (Liters and % of predicted value), the FVC (Liters and % of predicted value), the RV (Liters and % of predicted value), the TLC (Liters and % of predicted value) obtained by spirometry/plethysmography.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>COPD</condition>
  <condition>Emphysema</condition>
  <condition>Right Heart Dysfunction</condition>
  <arm_group>
    <arm_group_label>COPD patients</arm_group_label>
    <description>COPD patients with severe emphysema and right heart dysfunction</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        COPD patients with severe emphysema and right heart dysfunction&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  At least 40 years&#xD;
&#xD;
          -  A smoking history&#xD;
&#xD;
          -  Smoking cessation ≥ 6 months&#xD;
&#xD;
          -  FEV1/FVC ≤ 0,7&#xD;
&#xD;
          -  Severe emphysema (destruction ≥ 50%)&#xD;
&#xD;
          -  Peak tricuspid regurgitation velocity &lt; 2,8 m/s or presence of other echocardiographic&#xD;
             &quot;PH signs&quot;&#xD;
&#xD;
          -  15% ≤ FEV1post ≤ 50%&#xD;
&#xD;
          -  Residual volume ≥ 175% predicted&#xD;
&#xD;
          -  TLC ≥ 100% predicted&#xD;
&#xD;
          -  Optimal medical management&#xD;
&#xD;
          -  150m ≤ 6MWD ≤ 500m&#xD;
&#xD;
          -  mMRC ≥ 2&#xD;
&#xD;
          -  Physical activity ≥ 2/Week (≥ 30minutes)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  ≥2 hospitalizations/year for EACOPD&#xD;
&#xD;
          -  Recent EACOPD (≤ 3months)&#xD;
&#xD;
          -  ≥ 50ml mucus/day&#xD;
&#xD;
          -  PAPm ≥35mmHg&#xD;
&#xD;
          -  PaCO2 ≥ 55mmHg&#xD;
&#xD;
          -  Bubble ≥ 1/3 hemithorax&#xD;
&#xD;
          -  Lung fibrosis, bronchiectasis, lung cancer, homolateral surgery&#xD;
&#xD;
          -  Left ventricular ejection fraction ≤ 45%, unstable heart disease&#xD;
&#xD;
          -  Life expectancy ≤ 1 year&#xD;
&#xD;
          -  Contraindication to anesthesia&#xD;
&#xD;
          -  Allergy to nitinol or silicone&#xD;
&#xD;
          -  Corticotherapy ≥ 10mg/day&#xD;
&#xD;
          -  Patient under legal protection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnaud Bourdin, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arnaud Bourdin, MD PhD</last_name>
    <phone>467336091</phone>
    <phone_ext>33</phone_ext>
    <email>a-bourdin@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Uh Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud BOURDIN, MD PhD</last_name>
      <phone>46733609</phone>
      <phone_ext>33</phone_ext>
      <email>a-bourdin@chu-montpellier.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 1, 2020</study_first_submitted>
  <study_first_submitted_qc>July 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2020</study_first_posted>
  <last_update_submitted>November 27, 2020</last_update_submitted>
  <last_update_submitted_qc>November 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Emphysema</mesh_term>
    <mesh_term>Emphysema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

